Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review
Abstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk. Bromocriptine has been in clinical use for over 30 years, but the utility...
Main Authors: | Mulualem Tesfaye Birhan, Teklie Mengie Ayele, Fikire Wondimu Abebe, Fiseha Nigussie Dgnew |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-023-01073-2 |
Similar Items
-
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Via MA
Published: (2010-03-01) -
Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
by: O A Gerasimenko, et al.
Published: (2011-12-01) -
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
by: Michael Ezrokhi, et al.
Published: (2021-06-01) -
Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
by: Anthony H. Cincotta
Published: (2023-08-01) -
A Case Report of Trigeminal Neuralgia after Taking Bromocriptine
by: Reza Bavarsad Shahripour
Published: (2011-07-01)